CA2513143A1 - Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers - Google Patents

Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Download PDF

Info

Publication number
CA2513143A1
CA2513143A1 CA002513143A CA2513143A CA2513143A1 CA 2513143 A1 CA2513143 A1 CA 2513143A1 CA 002513143 A CA002513143 A CA 002513143A CA 2513143 A CA2513143 A CA 2513143A CA 2513143 A1 CA2513143 A1 CA 2513143A1
Authority
CA
Canada
Prior art keywords
cancer
cell
hyaluronan
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513143A
Other languages
English (en)
French (fr)
Inventor
Bryan P. Toole
Suniti Misra
Shibnath Ghatak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2513143A1 publication Critical patent/CA2513143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002513143A 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Abandoned CA2513143A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39290502P 2002-07-01 2002-07-01
US60/392,905 2002-07-01
US45376103P 2003-03-11 2003-03-11
US60/453,761 2003-03-11
PCT/US2003/020918 WO2004003545A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Publications (1)

Publication Number Publication Date
CA2513143A1 true CA2513143A1 (en) 2004-01-08

Family

ID=30003285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513143A Abandoned CA2513143A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Country Status (6)

Country Link
US (2) US8093217B2 (enExample)
EP (2) EP1532434A4 (enExample)
JP (2) JP5027387B2 (enExample)
AU (1) AU2003280471B2 (enExample)
CA (1) CA2513143A1 (enExample)
WO (1) WO2004003545A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
WO2006033693A2 (en) * 2004-06-30 2006-03-30 Deangelis Paul L Methods of selectively treating diseases with specific glycosaminoglycan polymers
WO2006128041A2 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
CA2701601C (en) * 2006-10-03 2020-06-30 The Board Of Regents Of The University Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
WO2008140586A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
EP2307571A4 (en) * 2008-06-26 2012-03-07 Univ South Florida PROOF AND SENSITIZATION PROCEDURE FOR THE PLATINUM RESISTANCE OF CANCER DISORDERS
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
US10766927B2 (en) 2012-11-25 2020-09-08 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
AU2014293013A1 (en) * 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
WO2016151478A1 (en) 2015-03-20 2016-09-29 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
AU4071197A (en) * 1996-08-16 1998-03-06 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Also Published As

Publication number Publication date
JP2005532373A (ja) 2005-10-27
EP1532434A4 (en) 2009-05-27
US8648047B2 (en) 2014-02-11
AU2003280471A1 (en) 2004-01-19
JP2010116410A (ja) 2010-05-27
US20040229843A1 (en) 2004-11-18
JP5027387B2 (ja) 2012-09-19
EP2434282A2 (en) 2012-03-28
US20120095277A1 (en) 2012-04-19
WO2004003545A9 (en) 2004-04-15
US8093217B2 (en) 2012-01-10
AU2003280471B2 (en) 2009-04-23
EP1532434A1 (en) 2005-05-25
EP2434282A3 (en) 2012-08-22
WO2004003545A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
US8648047B2 (en) Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
Zheng et al. Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages
Munshi et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
Vaisitti et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor
US12523647B2 (en) Method for evaluating anticancer effect and method for predicting effectiveness of cancer immunotherapy
EP1119349B1 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
Bizzarro et al. Mesoglycan induces keratinocyte activation by triggering syndecan‐4 pathway and the formation of the annexin A1/S100A11 complex
Fontana et al. PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma
KR102857853B1 (ko) 암 조직 또는 암 조직과 유사한 조직의 배양 방법
Keysar et al. Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma
Kim et al. Combined inhibition of topoisomerase I and poly (ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency
Razonable et al. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines
Deng et al. Inhibition of colorectal cancer aggressiveness by Oleanolic acid through Nur77 degradation
Booth et al. GZ17-6.02 kills PDX isolates of uveal melanoma
Kim et al. Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non–small cell lung cancer
Wang et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines
WO2016100431A1 (en) Methods for treating inflammatory arthritis
Kim et al. Hyaluronic acid fuels pancreatic cancer growth
Ma et al. Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin
EP3760197B1 (en) Transport protein inhibitor for reducing expression of pd-1
Szewczyk et al. Optimizing Jasplakinolide delivery in rhabdomyosarcoma cells using pulsed electric fields (PEFs) for enhanced therapeutic impact
Sinha et al. Collagen gel culture of rat mammary tumor cells as an assay system for determination of therapeutic efficacy of chemotherapeutic agents
Liu et al. Calcitonin receptor‐mediated CFTR activation in human intestinal epithelial cells
US20240166702A1 (en) Compositions and methods for treating breast cancer
US20240226234A1 (en) Wnt5a peptides for the treatment of acute myelogenous leukemia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160704